BioNTech / Biopharmaceutical New Technologies

CLDN6-specific CAR-T cells plus amplifying RNA vaccine in relapsed or refractory solid tumors: the phase 1 BNT211-01 trial (2023) Mackensen A, Haanen JB, Koenecke C, Alsdorf W, Wagner-Drouet E, Borchmann P, Heudobler D, et al. Journal article Multifunctional mRNA-Based CAR T Cells Display Promising Antitumor Activity against Glioblastoma (2022) Meister H, Look T, Roth P, Pascolo S, Sahin U, Lee S, Hale BD, et al. Journal article BNT211-01: A phase I trial to evaluate safety and efficacy of CLDN6 CAR T cells and CLDN6-encoding mRNA vaccine-mediated in vivo expansion in patients with CLDN6-positive advanced solid tumours (2022) Mackensen A, Haanen JBAG, Koenecke C, Alsdorf W, Wagner-Drouet E, Heudobler D, Borchmann P, et al. Conference contribution BNT211: A phase I/II trial to evaluate safety and efficacy of CLDN6 CAR-T cells and CARVac-mediated in vivo expansion in patients with CLDN6+advanced solid tumors (2021) Haanen J, Mackensen A, Koenecke C, Alsdorf W, Desuki A, Wagner-Drouet E, Heudobler D, et al. Conference contribution BNT211: A PHASE I/II TRIAL TO EVALUATE SAFETY AND EFFICACY OF CLDN6 CAR-T CELLS AND VACCINE-MEDIATED IN VIVO EXPANSION IN PATIENTS WITH CLDN6-POSITIVE ADVANCED SOLID TUMORS (2021) Mackensen A, Koenecke C, Haanen J, Alsdorf W, Desuki A, Wagner-Drouet E, Heudobler D, et al. Conference contribution A transplantable tumor model allowing investigation of NY-BR-1-specific T cell responses in HLA-DRB1*0401 transgenic mice (2019) Das K, Eisel D, Vormehr M, Mueller-Decker K, Hommertgen A, Jaeger D, Zoernig I, et al. Journal article Evaluation of the MammaTyperVR as a molecular predictor for pathological complete response (pCR) after neoadjuvant chemotherapy (NACT) and outcome in patients with different breast cancer (BC) subtypes (2018) Fasching P, Laible M, Weber KE, Wirtz RM, Denkert C, Schlombs K, Schmatloch S, et al. Conference contribution Validation of the MammaTyper (R) pathological complete response (pCR)-score as a predictor for response after neoadjuvant chemotherapy (NACT) in patients with early breast cancer (BC) (2018) Fasching P, Laible M, Weber KE, Wirtz RM, Denkert C, Schlombs K, Schmatloch S, et al. Conference contribution ERBB2 Expression as Potential Risk-Stratification for Early Cystectomy in Patients with pT1 Bladder Cancer and Concomitant Carcinoma in situ (2017) Breyer J, Otto W, Wirtz RM, Wullich B, Keck B, Erben P, Kriegmair MC, et al. Journal article Predictive value of molecular subtyping in NMIBC by RT-qPCR of ERBB2, ESR1, PGR and MKI67 from formalin fixed TUR biopsies (2017) Breyer J, Wirtz RM, Otto W, Laible M, Schlombs K, Erben P, Kriegmair MC, et al. Journal article